Last $0.68 USD
Change Today +0.053 / 8.45%
Volume 544.9K
IBIO On Other Exchanges
Symbol
Exchange
NYSE Amex
Berlin
As of 4:15 PM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

ibio inc (IBIO) Key Developments

Levi & Korsinsky Announces Class Action Lawsuit iBio, Inc

Levi & Korsinsky announced that a class action lawsuit has been commenced in the United States District Court for the District of Delaware on behalf of investors who purchased iBio, Inc. securities between October 13, 2014 and October 23, 2014. The complaint alleges that during the class period, the company issued materially false and misleading statements to investors by wrongfully suggesting that the company's launch platform patents and related proprietary technology would be licensed by the makers of the experimental Ebola drug, ZMapp. The complaint alleges that when the true facts were revealed, the price of the company's stock fell significantly, damaging investors.

iBio, Inc., Annual General Meeting, Dec 10, 2014

iBio, Inc., Annual General Meeting, Dec 10, 2014., at 10:00 US Eastern Standard Time. Location: Omni Berkshire Place Hotel, 21 East 52 Street. Agenda: To elect two directors each to serve as Class III directors for a three year term expiring at the 2017 annual meeting of stockholders or until successors have been duly elected and qualified; to ratify the appointment of CohnReznick LLP as the company's independent registered public accounting firm for the fiscal year ending June 30, 2015; to approve an advisory vote on executive compensation; and to transact any other business properly brought before the annual meeting.

The Rosen Law Firm Files Class Action Lawsuit Against iBio, Inc

The Rosen Law Firm announced that it has filed a class action lawsuit against iBio, Inc. on behalf of all purchasers of the company's common stock between October 13, 2014 and October 23, 2014, inclusive. The lawsuit seeks to recover damages for iBio shareholders under the federal securities laws. The suit is pending in U.S. District Court for the District of Delaware. The lawsuit claims that iBio issued materially false and misleading statements to investors by wrongfully suggesting that iBio's Launch platform patents and related proprietary technology would be licensed by the makers of the experimental Ebola drug, ZMapp. The lawsuit claims that when the true facts were revealed, the price of iBio's stock dropped, damaging investors.

iBio, Inc. Expands Exclusive Product Collaboration With Novici Biotech LLC

iBio, Inc. and Novici Biotech LLC (Novici) have agreed to broaden their commercial collaboration, currently focused on antibodies and certain vaccine products, to include iBio's proprietary IBIO-CFB03 product for idiopathic pulmonary fibrosis, systemic sclerosis and other fibrotic diseases. This expanded program will combine the strength of the iBioLaunch(TM) platform with Novici's patented GRAMMR(R) technology for rapid evolution of gene sequences to significantly increase expression yield of target proteins. IBIO-CFB03 and related proteins have been produced in plants on the iBioLaunch platform substantially more quickly and cost-effectively than has been possible with traditional methods. By combining the strengths of the iBioLaunch platform with Novici's GRAMMR technology, iBio expects to drive production efficiency even further as the fibrosis team initiates expanded animal testing and additional IND-enabling tasks.

Thomas A. Medsger Joins iBio, Inc.'s Clinical Advisory Board

iBio, Inc. has appointed Thomas A. Medsger Jr., M.D., to its clinical advisory board. Dr. Medsger is an expert in systemic sclerosis and localized scleroderma. Dr. Medsger will provide iBio with guidance on the further development and commercialization of the company's novel drug candidate, IBIO-CFB03, for idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc), and other fibrotic diseases.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IBIO:US $0.68 USD +0.053

IBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IBIO.
View Industry Companies
 

Industry Analysis

IBIO

Industry Average

Valuation IBIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 40.3x
Price/Book 7.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 40.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IBIO INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.